248 related articles for article (PubMed ID: 19818262)
1. Position paper: the need for head-to-head studies comparing Avastin versus Lucentis.
Schmucker C; Antes G; Lelgemann M
Surv Ophthalmol; 2009; 54(6):705-7. PubMed ID: 19818262
[No Abstract] [Full Text] [Related]
2. Avastin versus Lucentis: ethical issues in treatment of age-related macular degeneration.
Klein RM; Klein RB
Retina; 2007; 27(9):1163-5. PubMed ID: 18046218
[No Abstract] [Full Text] [Related]
3. Intravitreal avastin: the low cost alternative to lucentis?
Rosenfeld PJ
Am J Ophthalmol; 2006 Jul; 142(1):141-3. PubMed ID: 16815262
[No Abstract] [Full Text] [Related]
4. Avastin versus Lucentis: ethical issues.
Wong HC
Retina; 2008; 28(7):1024-5; author reply 1025. PubMed ID: 18698312
[No Abstract] [Full Text] [Related]
5. Cheap shots and pricey propositions: evidence, disclosure, and treatment of age-related macular degeneration.
Kimmelman J
Retina; 2007; 27(9):1166-7. PubMed ID: 18046219
[No Abstract] [Full Text] [Related]
6. Intravitreal VEGF-inhibitors: is Avastin a generic substitute for Lucentis?
la Cour M
Acta Ophthalmol Scand; 2007 Feb; 85(1):2-4. PubMed ID: 17244202
[No Abstract] [Full Text] [Related]
7. Comparing ranibizumab with bevacizumab.
Biswas P; Sengupta S; Choudhary R; Home S; Paul A; Sinha S
Ophthalmology; 2011 Mar; 118(3):600-600.e2. PubMed ID: 21376243
[No Abstract] [Full Text] [Related]
8. Ranibizumab versus bevacizumab for the treatment of neovascular age-related macular degeneration.
Abouammoh M; Sharma S
Curr Opin Ophthalmol; 2011 May; 22(3):152-8. PubMed ID: 21483262
[TBL] [Abstract][Full Text] [Related]
9. Value-based medicine.
Kymes SM; Vollman D; Frick KD
Ophthalmology; 2008 Nov; 115(11):2099; author reply 2100. PubMed ID: 19068385
[No Abstract] [Full Text] [Related]
10. Some ethical considerations for the "off-label" use of drugs such as Avastin.
Wong D; Kyle G
Br J Ophthalmol; 2006 Oct; 90(10):1218-9. PubMed ID: 16980641
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab: a new way of doing business?
Canning C; Lotery A
Eye (Lond); 2006 Sep; 20(9):985-7. PubMed ID: 16858443
[TBL] [Abstract][Full Text] [Related]
12. Comparing treatments for age-related macular degeneration: safety, effectiveness and cost.
Maguire MG
LDI Issue Brief; 2012 Jun; 17(8):1-4. PubMed ID: 22754971
[TBL] [Abstract][Full Text] [Related]
13. FDA. Once on 'fast track,' avastin now derailed.
Couzin-Frankel J; Ogale Y
Science; 2011 Jul; 333(6039):143-4. PubMed ID: 21737712
[No Abstract] [Full Text] [Related]
14. Avastin and new treatments for AMD: where are we?
Freeman WR; Falkenstein I
Retina; 2006 Oct; 26(8):853-8. PubMed ID: 17031283
[No Abstract] [Full Text] [Related]
15. Intravitreal bevacizumab for parapapillary choroidal neovascularization due to exudative age-related macular degeneration.
Jonas JB; Tao Y; Rensch F
Acta Ophthalmol; 2011 Feb; 89(1):e105-7. PubMed ID: 20064119
[No Abstract] [Full Text] [Related]
16. Should Avastin be used to treat age-related macular degeneration in the NHS?--Yes.
Raftery J; Dent L
Eye (Lond); 2009 Jun; 23(6):1247-9. PubMed ID: 19407834
[No Abstract] [Full Text] [Related]
17. Choroidal neovascularization in pathologic myopia.
Dave V; Narayanan R
Am J Ophthalmol; 2010 Nov; 150(5):752; author reply 752-3. PubMed ID: 21036211
[No Abstract] [Full Text] [Related]
18. Controversies in the treatment of wet age-related macular degeneration.
Moreno SF; Paloma JB
Am J Ophthalmol; 2008 May; 145(5):937; author reply 938. PubMed ID: 18435977
[No Abstract] [Full Text] [Related]
19. A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration.
Brown MM; Brown GC; Brown HC; Peet J
Ophthalmology; 2008 Jun; 115(6):1039-1045.e5. PubMed ID: 17976724
[TBL] [Abstract][Full Text] [Related]
20. CATT: Into the eye of a tiger.
Sears J; Bena J; Singh AD
Br J Ophthalmol; 2011 Jun; 95(6):761. PubMed ID: 21602481
[No Abstract] [Full Text] [Related]
[Next] [New Search]
